I am an established investigator in the epidemiology, economics, and outcomes of rheumatic diseases, particularly systemic lupus erythematosus (SLE).

We have produced standardized measures for lupus disease activity and damage that are fundamental to all lupus research and conducted pivotal longitudinal cohort studies on cardiovascular, neuropsychiatric, renal, and economic outcomes. I have contributed to an international task force (Definition of Remission in SLE: DORIS) that is re-defining optimal management strategies in SLE. Through numerous national and international collaborations, my research team has assembled the largest-ever international SLE cohort and provided the first definitive evidence on the association between SLE and malignancy. I have received support from numerous Canadian and American peer-reviewed granting agencies and charitable organizations, have published over 400 manuscripts, and am very engaged in the training of the next generation of lupus clinicians and investigators.